- Home
- QUIK vs ZNTL Comparison
QUIK vs ZNTL Comparison
Compare QUIK & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- ZNTL
- Stock Information
- Founded
- QUIK 1988
- ZNTL 2014
- Country
- QUIK United States
- ZNTL United States
- Employees
- QUIK N/A
- ZNTL N/A
- Industry
- QUIK Semiconductors
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- ZNTL Health Care
- Exchange
- QUIK Nasdaq
- ZNTL Nasdaq
- Market Cap
- QUIK 87.3M
- ZNTL 102.2M
- IPO Year
- QUIK 1997
- ZNTL 2020
- Fundamental
- Price
- QUIK $5.90
- ZNTL $1.23
- Analyst Decision
- QUIK Strong Buy
- ZNTL Buy
- Analyst Count
- QUIK 3
- ZNTL 8
- Target Price
- QUIK $11.53
- ZNTL $8.53
- AVG Volume (30 Days)
- QUIK 94.9K
- ZNTL 752.0K
- Earning Date
- QUIK 05-13-2025
- ZNTL 05-20-2025
- Dividend Yield
- QUIK N/A
- ZNTL N/A
- EPS Growth
- QUIK N/A
- ZNTL N/A
- EPS
- QUIK N/A
- ZNTL N/A
- Revenue
- QUIK $20,112,000.00
- ZNTL $67,425,000.00
- Revenue This Year
- QUIK $22.56
- ZNTL N/A
- Revenue Next Year
- QUIK $21.66
- ZNTL N/A
- P/E Ratio
- QUIK N/A
- ZNTL N/A
- Revenue Growth
- QUIK N/A
- ZNTL N/A
- 52 Week Low
- QUIK $4.26
- ZNTL $1.01
- 52 Week High
- QUIK $16.13
- ZNTL $13.24
- Technical
- Relative Strength Index (RSI)
- QUIK 59.62
- ZNTL 38.08
- Support Level
- QUIK $5.31
- ZNTL $1.33
- Resistance Level
- QUIK $5.98
- ZNTL $1.32
- Average True Range (ATR)
- QUIK 0.35
- ZNTL 0.10
- MACD
- QUIK 0.12
- ZNTL -0.00
- Stochastic Oscillator
- QUIK 83.53
- ZNTL 8.22
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.